News

Article

Zeteo Biomedical secures US and EU patents for drug delivery technologies

Author(s):

(Image Credit: AdobeStock/ronstik)

(Image Credit: AdobeStock/ronstik)

Zeteo Biomedical recently received new patents for its drug delivery technologies ZTech portfolio in both the United States and European Union.1 The first patent is titled “Cartridge Devices for Administration of a Medicament” (US Patent No. 12329949), and the second patent is titled “Hand-Operated Device for Administration of a Medicament” (EU Patent No. 3946526).

The patents allow Zeteo to further expand and strengthen its ZTech drug delivery platform portfolio, advancing the technologies of ZTech-L and ZTech-P, both of which include single-use disposable and multi-dose, cartridge-reloadable handheld devices.

“We are seeing increasing global demand for metered-dose nasal, ophthalmic and sublingual delivery devices that are compact, intuitive, and suitable for self-administration,” said Timothy Sullivan, chief executive officer of Zeteo Biomedical.

“A unique feature that sets our device technology apart is its ability to function reliably in any physical orientation, making it ideal for medication delivery in both terrestrial and space-based microgravity environments. This capability opens exciting new frontiers for Zeteo including applications in space-based healthcare.”

The technologies of ZTech-L and ZTech-P support administering therapeutics in both liquid and dry powder formulations, including vaccines, biologics and specialty drugs. Zeteo noted in a press release that nasal delivery is particularly a highly effective, non-invasive alternative for the treatment of conditions like pain, emesis, seizures, neurodegenerative and autoimmune disorders, infectious diseases and bioterror threats.

Based in Texas, Zeteo’s platform technologies aim to meet the ever-evolving demands of healthcare markets globally, “delivering precision, performance, and portability for the next-generation of therapeutic drug/device combination products,” a press release said. Zeteo’s technology focuses on patient-friendly design, which can improve treatment adherence and medical outcomes.

Reference:
  1. Sullivan T. Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations. Zeteo Biomedical. Published June 11, 2025. Accessed June 11, 2025. https://zeteobiomed.com/2025/06/zeteo-biomedical-secures-global-patents-for-nasal-and-ophthalmic-drug-delivery-device-innovations/

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.